Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

4D Molecular Therapeutics (FDMT) Return on Equity (2020 - 2025)

4D Molecular Therapeutics (FDMT) has disclosed Return on Equity for 6 consecutive years, with 0.32% as the latest value for Q4 2025.

  • Quarterly Return on Equity fell 2.0% to 0.32% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.32% through Dec 2025, down 2.0% year-over-year, with the annual reading at 0.28% for FY2025, 12.0% up from the prior year.
  • Return on Equity for Q4 2025 was 0.32% at 4D Molecular Therapeutics, up from 0.53% in the prior quarter.
  • The five-year high for Return on Equity was 0.18% in Q2 2024, with the low at 0.53% in Q3 2025.
  • Average Return on Equity over 5 years is 0.33%, with a median of 0.31% recorded in 2024.
  • Peak annual rise in Return on Equity hit 49bps in 2021, while the deepest fall reached -64bps in 2021.
  • Over 5 years, Return on Equity stood at 0.26% in 2021, then crashed by -70bps to 0.45% in 2022, then grew by 29bps to 0.32% in 2023, then increased by 4bps to 0.3% in 2024, then dropped by -6bps to 0.32% in 2025.
  • According to Business Quant data, Return on Equity over the past three periods came in at 0.32%, 0.53%, and 0.44% for Q4 2025, Q3 2025, and Q2 2025 respectively.